Eupraxia Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
201-2067 Cadboro Bay Rd, Victoria, Briti...Phone Number
(250) 590-3968Website
www.eupraxiapharma.comRevenue
$6.1 MillionStock Symbol
EPRXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.Explore more
Eupraxia Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eupraxia Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Eupraxia Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Eupraxia Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Eupraxia Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Eupraxia Pharmaceuticals has new funding data
Product Launch: Get notified when Eupraxia Pharmaceuticals launches new products
Check out if Eupraxia Pharmaceuticals is spiking on competitors!
Recommended Actions
Find VP level buyers at Eupraxia Pharmaceuticals
Find 3 more new buyers
Compare Similar Companies to Eupraxia Pharmaceuticals
Compare insights from companies similar to Eupraxia Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Eupraxia Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Eupraxia Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Eupraxia Pharmaceuticals.
Eupraxia Pharmaceuticals financials insights
Gather financial insights about Eupraxia Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$8M
2024
Share Placement
$62M
Eupraxia Pharmaceuticals Tech Stack
A closer look at the technologies used by Eupraxia Pharmaceuticals
See more technologies
Most Recent Scoops
Project
Eupraxia Pharmaceuticals has attributed the delayed peak in symptom improvement observed in Phase IIa from 2 weeks to 6 months to the drug's dual mechanism of reducing inflammation and reversing fibrosis.
Medical Research, Pharmaceuticals
Project
Eupraxia Pharmaceuticals has anticipated an End of Phase II regulatory meeting in H1 2027, with Phase III expected to be a single registrational trial of approximately 300 patients using a single dose selected based on Phase IIb results.
Pharmaceuticals, Clinical Operations
Project
Eupraxia Pharmaceuticals has reported that procedural adverse events in its eosinophilic esophagitis clinical program were limited to approximately 20% of patients experiencing sore throat lasting approximately 24 hours, consistent with the rate observed in patients undergoing endoscopy without the drug procedure, and with no increase in post-procedure recovery time.
Pharmaceuticals, Clinical Operations
Project
Eupraxia Pharmaceuticals has outlined near-term development, including an additional Phase IIa data release in Q3 of the current year and a Phase IIb interim data cut in Q4 of the current year covering patients at 6 months, 9 months, and 1 year, plus crossover patients.
Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals, Clinical Operations
Eupraxia Pharmaceuticals News & Media
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors.Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General Meeting of Shareholders (the “Meeting”) held on June 18, 2026.Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company’s management team will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026.Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI
Read more news
Top Business Services Companies
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Eupraxia Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-... Read More
